{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:57:37Z","timestamp":1793465857171,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12328-021-01543-y","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T18:02:35Z","timestamp":1635357755000},"page":"134-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pathological complete response to pembrolizumab in patients with metastatic ascending colon cancer with microsatellite instability"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-3227","authenticated-orcid":false,"given":"Tetsuro","family":"Tominaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shosaburo","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumitsu","family":"Sawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nagayasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"1543_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1543_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.6004\/jnccn.2017.0036","volume":"15","author":"AB Benson 3rd","year":"2017","unstructured":"Benson AB 3rd, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Comp Canc Netw. 2017;15:370\u201398.","journal-title":"J Natl Comp Canc Netw"},{"key":"1543_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/s-0038-1673355","volume":"32","author":"MC Daly","year":"2019","unstructured":"Daly MC, Paquette IM. Surveillance, epidemiology, and end results (SEER) and SEER-Medicare databases: use in clinical research for improving colorectal cancer outcomes. Clin Colon Rectal Surg. 2019;32:61\u20138.","journal-title":"Clin Colon Rectal Surg"},{"key":"1543_CR4","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"key":"1543_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313.","journal-title":"Science"},{"key":"1543_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11\u20139.","journal-title":"J Clin Oncol"},{"key":"1543_CR7","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. NEJM. 2020;383:2207\u201318.","journal-title":"NEJM"},{"key":"1543_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","volume":"100","author":"M Koopman","year":"2009","unstructured":"Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266\u201373.","journal-title":"Br J Cancer"},{"key":"1543_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.21037\/jgo.2018.09.19","volume":"10","author":"C Wang","year":"2019","unstructured":"Wang C, Sandhu J, Fakih M. Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. J Gastrointest Oncol. 2019;10:161\u20135.","journal-title":"J Gastrointest Oncol"},{"key":"1543_CR10","first-page":"3847672","volume":"2019","author":"M Keating","year":"2019","unstructured":"Keating M, Giscombe L, Tannous T, et al. Prolonged treatment response to pembrolizumab in a patient with pretreated metastatic colon cancer and lynch syndrome. Case Rep Oncol Med. 2019;2019:3847672.","journal-title":"Case Rep Oncol Med"},{"key":"1543_CR11","doi-asserted-by":"publisher","first-page":"e000084","DOI":"10.1136\/esmoopen-2016-000084","volume":"1","author":"M Kieler","year":"2016","unstructured":"Kieler M, Scheithauer W, Zielinski CC, et al. Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease. ESMO Open. 2016;1:e000084.","journal-title":"ESMO Open"},{"key":"1543_CR12","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMp1709968","volume":"377","author":"S Lemery","year":"2017","unstructured":"Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site\u2014when a biomarker defines the indication. N Engl J Med. 2017;377:1409\u201312.","journal-title":"N Engl J Med"},{"key":"1543_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/annonc\/mdi092","volume":"16","author":"T Delaunoit","year":"2005","unstructured":"Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005;16:425\u20139.","journal-title":"Ann Oncol"},{"key":"1543_CR14","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1245\/s10434-011-2061-0","volume":"19","author":"VW Lam","year":"2012","unstructured":"Lam VW, Spiro C, Laurence JM, et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol. 2012;19:1292\u2013301.","journal-title":"Ann Surg Oncol"},{"key":"1543_CR15","first-page":"cd011134","volume":"2015","author":"BD Nicholson","year":"2015","unstructured":"Nicholson BD, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015;2015:cd011134.","journal-title":"Cochrane Database Syst Rev"},{"key":"1543_CR16","first-page":"14","volume":"47","author":"V Kalff","year":"2006","unstructured":"Kalff V, Duong C, Drummond EG, et al. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med. 2006;47:14\u201322.","journal-title":"J Nucl Med"},{"key":"1543_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.radonc.2010.12.002","volume":"98","author":"RG van Stiphout","year":"2010","unstructured":"van Stiphout RG, Lammering G, Buijsen J, et al. Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother Oncol. 2010;98:126\u201333.","journal-title":"Radiother Oncol"},{"key":"1543_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jclinpath-2018-205143","volume":"71","author":"DM Karamchandani","year":"2018","unstructured":"Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists\u2019 perspective. J Clin Pathol. 2018;71:665\u201371.","journal-title":"J Clin Pathol"},{"key":"1543_CR19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.cgh.2015.12.028","volume":"14","author":"EC Verschuren","year":"2016","unstructured":"Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol. 2016;14:836\u201342.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1543_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","volume":"41","author":"JH Chen","year":"2017","unstructured":"Chen JH, Pezhouh MK, Lauwers GY, et al. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol. 2017;41:643\u201354.","journal-title":"Am J Surg Pathol"},{"key":"1543_CR21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/his.13118","volume":"70","author":"RS Gonzalez","year":"2017","unstructured":"Gonzalez RS, Salaria SN, Bohannon CD, et al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of \u201cimmunomodulatory gastroenterocolitis.\u201d Histopathology. 2017;70:558\u201367.","journal-title":"Histopathology"},{"key":"1543_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","volume":"7","author":"P Xing","year":"2019","unstructured":"Xing P, Zhang F, Wang G, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer. 2019;7:341.","journal-title":"J Immunother Cancer"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01543-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01543-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01543-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T06:27:23Z","timestamp":1645252043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01543-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01543-y","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"4 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of our Institutional Review Board and with the Helsinki Declaration of 1975, as revised in 2008(5).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights"}},{"value":"Informed consent was obtained from the patient for inclusion in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}